Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

228 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.
Tanaka A, Taguchi I, Teragawa H, Ishizaka N, Kanzaki Y, Tomiyama H, Sata M, Sezai A, Eguchi K, Kato T, Toyoda S, Ishibashi R, Kario K, Ishizu T, Ueda S, Maemura K, Higashi Y, Yamada H, Ohishi M, Yokote K, Murohara T, Oyama JI, Node K; PRIZE study investigators. Tanaka A, et al. Among authors: ishibashi r. PLoS Med. 2020 Apr 22;17(4):e1003095. doi: 10.1371/journal.pmed.1003095. eCollection 2020 Apr. PLoS Med. 2020. PMID: 32320401 Free PMC article. Clinical Trial.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial.
Kobayashi K, Yokoh H, Sato Y, Takemoto M, Uchida D, Kanatsuka A, Kuribayashi N, Terano T, Hashimoto N, Sakurai K, Hanaoka H, Ishikawa K, Onishi S, Yokote K; SUCCESS Study Group. Kobayashi K, et al. Diabetes Obes Metab. 2014 Aug;16(8):761-5. doi: 10.1111/dom.12264. Epub 2014 Feb 18. Diabetes Obes Metab. 2014. PMID: 24447683 Clinical Trial.
Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study).
Koshizaka M, Ishikawa K, Ishibashi R, Maezawa Y, Sakamoto K, Uchida D, Nakamura S, Yamaga M, Yokoh H, Kobayashi A, Onishi S, Kobayashi K, Ogino J, Hashimoto N, Tokuyama H, Shimada F, Ohara E, Ishikawa T, Shoji M, Ide S, Ide K, Baba Y, Hattori A, Kitamoto T, Horikoshi T, Shimofusa R, Takahashi S, Nagashima K, Sato Y, Takemoto M, Newby LK, Yokote K; PRIME-V Study Group. Koshizaka M, et al. Among authors: ishibashi r. Diabetes Obes Metab. 2019 Aug;21(8):1990-1995. doi: 10.1111/dom.13750. Epub 2019 May 8. Diabetes Obes Metab. 2019. PMID: 30993861 Free PMC article. Clinical Trial.
Safety and Efficacy of Ranibizumab and Luseogliflozin Combination Therapy in Patients with Diabetic Macular Edema: Protocol for a Multicenter, Open-Label Randomized Controlled Trial.
Ishibashi R, Takatsuna Y, Koshizaka M, Tatsumi T, Takahashi S, Nagashima K, Asaumi N, Arai M, Shimada F, Tachibana K, Watanabe Y, Ishikawa K, Hoshino A, Yamamoto K, Kubota-Taniai M, Mayama T, Yamamoto S, Yokote K. Ishibashi R, et al. Diabetes Ther. 2020 Aug;11(8):1891-1905. doi: 10.1007/s13300-020-00854-6. Epub 2020 Jun 15. Diabetes Ther. 2020. PMID: 32542431 Free PMC article.
Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study).
Koshizaka M, Ishikawa K, Ishibashi R, Maezawa Y, Sakamoto K, Uchida D, Nakamura S, Yamaga M, Yokoh H, Kobayashi A, Onishi S, Kobayashi K, Ogino J, Hashimoto N, Tokuyama H, Shimada F, Ohara E, Ishikawa T, Shoji M, Ide S, Ide K, Baba Y, Hattori A, Kitamoto T, Horikoshi T, Shimofusa R, Takahashi S, Nagashima K, Sato Y, Takemoto M, Newby LK, Yokote K; PRIME-V study group. Koshizaka M, et al. Among authors: ishibashi r. J Diabetes Investig. 2021 Feb;12(2):200-206. doi: 10.1111/jdi.13340. Epub 2020 Aug 20. J Diabetes Investig. 2021. PMID: 32623839 Free PMC article. Clinical Trial.
Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled Study.
Koshizaka M, Ishikawa K, Ishibashi R, Takahashi S, Sakamoto K, Yokoh H, Baba Y, Ide S, Ide K, Ishikawa T, Onishi S, Kobayashi K, Takemoto M, Horikoshi T, Shimofusa R, Maezawa Y, Yokote K. Koshizaka M, et al. Among authors: ishibashi r. Diabetes Ther. 2021 Jan;12(1):183-196. doi: 10.1007/s13300-020-00949-0. Epub 2020 Oct 24. Diabetes Ther. 2021. PMID: 33098565 Free PMC article.
Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Type 1 Diabetes Mellitus on Body Composition and Glucose Variabilities: Single-Arm, Exploratory Trial.
Baba Y, Ishibashi R, Takasaki A, Ito C, Watanabe A, Tokita M, Meguro M, Harama T, Hirayama K, Yamamoto T, Nakamura S, Koshizaka M, Maezawa Y, Uchida D, Okajima F. Baba Y, et al. Among authors: ishibashi r. Diabetes Ther. 2021 May;12(5):1415-1427. doi: 10.1007/s13300-021-01047-5. Epub 2021 Mar 18. Diabetes Ther. 2021. PMID: 33738773 Free PMC article.
228 results